Former Chief Executive Officer and President · Aclaris Therapeutics, Inc. (ACRS)

Douglas Manion

A named executive officer of Aclaris Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$856,081

Salary $27,083Stock awards $0

FY2023: $7,157,681

4th of 4 named executive officers at Aclaris Therapeutics by FY2024 total.

4 named officers on file for Aclaris Therapeutics, FY2024

Douglas Manion’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • ACRS’s disclosed peer group of 43 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Aclaris Therapeutics’s whole pay program stands against its peers

  • Aclaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ACRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A).

Free

Get Douglas Manion’s full pay file as a PDF — free

More than this page: up to 10 years of Douglas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Douglas Manion compensation by year

Aclaris Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Aclaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023FY2024
Salary$204,167$600,000$27,083
Bonus$0$0$0
Stock awards$848,526$1,832,760$0
Option awards$2,067,346$4,513,721$0
Non-equity incentive$82,159$198,000$0
Pension and deferred compensation$0$0$0
All other$0$13,200$828,998
Total$3,202,198$7,157,681$856,081

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Aclaris Therapeutics, Inc. DEF 14A filed April 24, 2025, accession 0001558370-25-005332, and prior-year filings.

How this page was built: the Aclaris Therapeutics, Inc. filed document, accession 0001558370-25-005332. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

$3.2M
$7.2M
$856K
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU108,000$113,400—
RSU46,725$49,061—
Option163,350—$13.62
Option378,000—$16.97

Per the Outstanding Equity Awards at Fiscal Year-End table in Aclaris Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Aclaris Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Hugh DavisPresident and Chief Operating Officer$1,595,185
Neal WalkerInterim Chief Executive Officer$1,445,135
Kevin BalthaserChief Financial Officer$1,102,163
Douglas Manion · this pageFormer Chief Executive Officer and President$856,081

Board service

Aclaris Therapeutics board · FY2024

How this board is paid

Company policy: Aclaris Therapeutics pays directors a $40,000 cash retainer and $320,000 in equity. As stated in Aclaris Therapeutics's FY2024 proxy.

The full Aclaris Therapeutics compensation record

free company brief

This page is one person within Aclaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Aclaris Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Aclaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Douglas Manion's compensation dossier · One-time report. No refunds.